Wegovy Wins English Funding For Weight Loss As Novo Deals With Supply Issues
Executive Summary
Unprecedented demand for Wegovy in the US, together with issues experienced at the contract manufacturing site that resulted in supply shortages, led to Novo Nordisk having to wait some time for NICE to publish its final recommendation for the drug’s use on the National Health Service in England.
You may also be interested in...
Can New Generation GLP-1s Overcome The Adherence Hurdle?
Novo Nordisk’s new generation of GLP-1 products have led to never-before-seen rates of medication-induced weight loss but require a lifelong commitment from patients to maintain these results – a commitment the market may not be able to rely on, since patients have not generally tended to stay on GLP-1 medications long-term.
‘Leaps of Faith:’ ICER Meeting Suggests Reimbursement Hurdles For NASH Drugs
Lack of long-term clinical outcomes data on a slowly progressing, common condition combined with a rapidly changing treatment space for obesity and health system cost issues may present problems for two NASH treatments even if they win accelerated approval from US FDA.
UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.